[
  {
    "ts": "2025-11-19T17:28:00+00:00",
    "headline": "Healthcare’s Momentum Gathers Steam. 3 Stocks With Bullish Charts.",
    "summary": "FEATURE  Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods.  The appeal of this group is its variety.",
    "url": "https://www.barrons.com/articles/healthcare-stocks-with-bullish-charts-7fbc45d1?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "71c4d3ec-b418-3d50-88a9-7444707dce8d",
      "content": {
        "id": "71c4d3ec-b418-3d50-88a9-7444707dce8d",
        "contentType": "STORY",
        "title": "Healthcare’s Momentum Gathers Steam. 3 Stocks With Bullish Charts.",
        "description": "",
        "summary": "FEATURE  Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods.  The appeal of this group is its variety.",
        "pubDate": "2025-11-19T17:28:00Z",
        "displayTime": "2025-11-19T17:28:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/71c4d3ec-b418-3d50-88a9-7444707dce8d/healthcare%E2%80%99s-momentum-gathers.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/13693cf05f3a91d9dcfb349ccd476d08",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jfamHCn4IqclY.b54hgmKQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/13693cf05f3a91d9dcfb349ccd476d08.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g6ybBWTGq7B76uvTMzTGtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/13693cf05f3a91d9dcfb349ccd476d08.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/healthcare-stocks-with-bullish-charts-7fbc45d1?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "XLV"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T21:01:00+00:00",
    "headline": "FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER",
    "summary": "Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to IMDELLTRA® (tarlatamab-dlle) for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. The decision to convert IMDELLTRA's prior accelerated approval to a full approval is based on data from the global Phase 3 DeLLphi-304 study. Additionally, the National Comprehensive Cancer Network® (",
    "url": "https://finance.yahoo.com/news/fda-grants-full-approval-amgens-210100904.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "28c53315-e533-3041-a1b6-dce731dc17da",
      "content": {
        "id": "28c53315-e533-3041-a1b6-dce731dc17da",
        "contentType": "STORY",
        "title": "FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER",
        "description": "",
        "summary": "Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to IMDELLTRA® (tarlatamab-dlle) for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. The decision to convert IMDELLTRA's prior accelerated approval to a full approval is based on data from the global Phase 3 DeLLphi-304 study. Additionally, the National Comprehensive Cancer Network® (",
        "pubDate": "2025-11-19T21:01:00Z",
        "displayTime": "2025-11-19T21:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/dd88fc63427022d71ca8183432abc09d",
          "originalWidth": 400,
          "originalHeight": 98,
          "caption": "Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9xF64eSNrBTdXVSUBRIisA--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/dd88fc63427022d71ca8183432abc09d.cf.webp",
              "width": 400,
              "height": 98,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LmrL8PQB2Q2cD.YsureBSw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/dd88fc63427022d71ca8183432abc09d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-grants-full-approval-amgens-210100904.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-grants-full-approval-amgens-210100904.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T19:46:00+00:00",
    "headline": "It Might Be Time to Buy Stocks Again. Even Tech.",
    "summary": "Investors must be patient and embrace diversification as they position themselves for a tech-stock rebound after this month’s slide. But they don‘t need an all-clear sign from  Nvidia  after the chip company’s earnings to wade back in.  There are plenty of good opportunities in the market, even in some of the beaten-up tech and artificial intelligence names.",
    "url": "https://www.barrons.com/articles/ai-trade-tech-stocks-nvidia-83fc0375?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "afe16196-b71f-3db9-9416-d2000f047ba3",
      "content": {
        "id": "afe16196-b71f-3db9-9416-d2000f047ba3",
        "contentType": "STORY",
        "title": "It Might Be Time to Buy Stocks Again. Even Tech.",
        "description": "",
        "summary": "Investors must be patient and embrace diversification as they position themselves for a tech-stock rebound after this month’s slide. But they don‘t need an all-clear sign from  Nvidia  after the chip company’s earnings to wade back in.  There are plenty of good opportunities in the market, even in some of the beaten-up tech and artificial intelligence names.",
        "pubDate": "2025-11-19T19:46:00Z",
        "displayTime": "2025-11-19T19:46:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/afe16196-b71f-3db9-9416-d2000f047ba3/it-might-be-time-to-buy.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/67e59641357cc00df63143393a6b977d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/f4byzg1MaTBO_w4gy9wPlA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/67e59641357cc00df63143393a6b977d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/P7w3FDy.CRMIOMEjfrPogA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/67e59641357cc00df63143393a6b977d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/ai-trade-tech-stocks-nvidia-83fc0375?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "SPG"
            },
            {
              "symbol": "SPG-PJ"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "NVR"
            },
            {
              "symbol": "META"
            },
            {
              "symbol": "TSLA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]